App-Quantinova.ai

Does Liver Stiffness Measurement and Controlled Attenuation Parameter predict portal hypertension, liver related events and overall mortality in individuals with cirrhosis?

Ahmed Hashim - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hepatic encephalopathy

N/A

Congenital extrahepatic portosystemic shunts (Abernethy malformation): International observational study of clinical manifestations and outcome.

Anna Baiges Aznar - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Cytokine Profile In Patients With Chronic Liver Disease and Sarcopenia.

Sarah E. Brown - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Chronic Liver Disease

Interferon Gamma

Ammonia is an important determinant of mortality in patients with acute deterioration of cirrhosis

Shalimar - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Cirrhosis

N/A

The impact of obesity in cirrhotic patients with septic shock: a retrospective cohort study

Beverley Kok - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Septic shock

N/A

In vitro efficacy of pro‐ and anticoagulant strategies in acutely ill patients with cirrhosis

Ton Lisman - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Acute on chronic liver failure

Prothrombin complex

A dedicated hostel‐based community liver service for Homeless and Vulnerable Adults: VALID (Vulnerable Adults LIver Disease) Study

Ahmed Hashim - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Hepatic fibrosis

N/A

Factors preventing testing for chronic viral hepatitis (CVH) in UK South‐Asians ‐ A novel National Institute for Health Research (NIHR) Study in a high risk group

Claire Kelly - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Antenatal Clinic: The ideal screening platform for alcohol related harm

Claire Kelly - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Alcohol Dependence

N/A

Assessment of non invasive markers of fibrosis against collagen quantitation and NASH‐CRN scoring in liver biopsies of NAFLD patients

Roberta Forlano - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic fatty liver disease

Desogestrel/ethinyl estradiol

Non‐viral Liver Disease Burden in HIV Mono‐infected Individuals: A Prospective Cohort Study

Dev Katarey - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Metabolic syndrome

N/A

Multiparametric magnetic resonance imaging can quantitatively assess fibroinflammatory response to direct acting antiviral treatment of hepatitis C virus.

Arjun N. Javaswal - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatic fibrosis

Desogestrel/ethinyl estradiol

Quantitative Non‐invasive Assessment of Liver Disease in Preclinical Models Using Multiparametric MR Imaging: A Feasibility Study

Anna M. Hoy - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic fatty liver disease

methionine

Alpha‐1 Antitrypsin improves engraftment in a rat model of hepatocyte transplantation through inhibition of the innate immune system

Charlotte A. Lee - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Alpha 1-Antitrypsin

A Novel inhibitory NK cell subpopulation is expanded in Cirrhosis

Naveenta Kumar - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Cirrhosis

Interferon Gamma

Circulating Natural Killer cells in Hepatocellular Carcinoma are hypofunctional with an exhausted phenotype

Naveenta Kumar - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Interferon Gamma

Mapping the heterogeneity of circulating neutrophils in Hepatocellular Carcinoma.

Caroline Wilson - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Liver cancer

N/A

The frequencies of total mucosal associated invariant T (MAIT) cells are significantly altered both in blood and liver of patients with primary sclerosing cholangitis

Yasmeen Ghnewa - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary sclerosing cholangitis

N/A

Acute adipocyte death causes liver inflammation and injury via the activation of macrophages: insight from a novel model of specific adipocyte death

Seung-Jin Kim - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic fatty liver disease

lipase

MDM2 inhibition for non‐genotoxic activation of TP53 ‐ a novel strategy for the treatment of hepatocellular carcinoma (HCC)

Ahmed K. Mahdi - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

HDM 201

Filters

45280 Abstracts